SOURCE: INVO Bioscience, Inc.

February 23, 2010 08:30 ET

INVO Bioscience Announces the Signing of Distribution Company Delfran Pharmaceuticals and First INVO Babies Born in Colombia

BEVERLY, MA--(Marketwire - February 23, 2010) -  INVO Bioscience, Inc. (OTCBB: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, announced today the signing of an agreement with a South African distribution company Delfran Pharmaceuticals (http://www.delfran.co.za/). Delfran is a drug and medical device distribution company that is looking to bring the low cost INVO procedure into African nations, making infertility treatment affordable to the general public. CEO Katie Karloff stated, "The shortage of a cost effective treatment has left assistance for many couples simply out of reach. We believe that INVO Bioscience partnered with Delfran can bring an affordable infertility procedure to couples in many areas of Africa."

Dr. Claude Ranoux, President and Chief Scientific Officer, traveled to Cape Town and Johannesburg, South Africa from February 7th-17th to perform distributor training.

Delfran Pharmaceuticals will have rights to distribute the INVOcell in the countries of South Africa, Madagascar, Seychelles, Mauritius, Namibia, Botswana, Mozambique, Kenya and Angola. The INVOcell product does not need registration in the African nations outlined in the agreement. The governments offer very little financial support for IVF and the vast majority of cases done are paid for privately. Delfran will look to introduce the INVO procedure first into South Africa and then plans to expand INVO into the other territories of Sub-Saharan Africa.

INVO is also happy to announce the birth of the first INVO babies in Colombia. The babies were born on February 15, 2010 to a couple who had been treated at the CECOLFES Center for Fertility in Colombia.

The mother had developed three Grade 1 embryos in her previous IVF attempt without achieving pregnancy. Due to her previous infertility history, after undergoing INVO she was transferred 3 embryos and this resulted in the birth of triplets. These triplets are a multiple pregnancy that occurred during the 50 patient study performed by CECOLFES. The two baby boys, baby girl and mother are doing well and were home from the Pereira Colombia hospital within a few days. Dr. Elkin Lucena, Laboratory Director of CECOLFES, said, "This is the beginning of a new era in ART and the beginning of more births that we're expecting from INVO in the following weeks."

About INVO Bioscience

INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information